Developing options for method of assessing the sensitivity of cells intracranial neoplasms to chemotherapeutics in vitro
https://doi.org/10.18027/2224-5057-2015-3-40-52
Abstract
Background
Neuroepithelial tumors are the most intractable to other types of cancer, especially in children and adolescents. One of the ways of increasing the efficacy of this type of tumors, the transition from group serves to a personalized therapy.
Objective
Develop and test version of the method in vitro evaluation of the sensitivity of neuroepithelial tumors cells to chemotherapy drugs and compare the characteristics of this method with other methods of determining the in vitro chemosensitivity of cells of different histological types of tumors.
Subjects and methods
For example, the primary cell cultures of intracranial tumors (ependymomas, anaplastic astrocytoma, glioblastoma, neuroblastoma, medulloblastoma, primitive neuroectodermal and atypical rhabdoid teratoid neoplasias) children (90) at the age 7,4 ± 1,1 years, developed and tested uproschnny option the analysis of their individual susceptibility and resistivity to chemotherapeutic drugs. Its essence consist of down to counting chamber Goryaeva proportion of dead (stained with trypan blue) and survivors (transparent) cells after their one-day exposure to cytotoxic drugs in doses that are close to the 50% lethal.
Results
Based on the gradation index of cytotoxicity of chemotherapeutic drugs and ex vivo evaluation of patients with cytotoxic drugs Supervision, according to accepted formulas were made calculations of sensitivity (67.2%), specificity (56.8%), positive (87.3%) and negative (26.6%) predictive value method.
Conclusion
The results were comparable to those of other more laborintensive methods, opening up the prospect of using this option for some of its technical development
About the Authors
A. N. CHERNOV
Institute of Physiology of the National Academy of Sciences of Belarus, Minsk, the Republic of Belarus
Russian Federation
Russian Federation
a researcher of neurophysiology laboratory tel: + 37529-394-10-95
V. N. KALJUNOV
Physiology of the National Academy of Sciences of Belarus, Minsk, the Republic of Belarus
Russian Federation
Russian Federation
Chief researcher of neurophysiology laboratory, Doctor of biological sciences (D. Sc), professor
N. E. KONOPLJA
Belorussian research center for pediatric oncology, hematology and immunology
Russian Federation
deputy of director, Doctor of medical sciences (D. Sc), Assistant of professor
Russian Federation
deputy of director, Doctor of medical sciences (D. Sc), Assistant of professor
References
1. Апшкалне Д. Л., Круминя Г. A., Kикут Р. П., Кoтельников В. M. Результаты клинического применения методов индивидуальной чувствительности химиотерапевтических препаратов для лечения глиом. Вопр. нейрохирургии им. Н. Н. Бурденко: 1980; 6: 7–12. Apshkalne D. L., Kruminya G. A., Kikut R. P., Kotelnikov V. M. Results of clinical application of individual sensitivity methods of chemotherapeutic agents for the treatment of gliomas. Voprosy Neyrohirurgii im.Burdenko N.N. [Burdenko N. N. Questions in Neurosurgery], 1980, № 6, pp.7–12.
2. Божкова В. П., Брежестовский П. Д., Буравлев В. П. и др. Руководство по культивированию нервной ткани. Методы. Техника. Проблемы; под ред.: Б. П. Вепринцева, И. В. Викторова, Б. Я. Вильнера. – М.: Наука, 1988. – 318 с. Bozhkova V. P., Brezhestovskyj P. D., Buravlev V. P. et al. “Rukovodstvo po kultivirovaniyu nrvnoy tkani. Metody. Tehnika. Problemy.” [“Guidelines for culturing neural tissue. Methods. Technics. Problems.”]. Moscow. Nauka Publ. 1988. – p.318.
3. Иншаков А. Н. Фармакодинамическое моделирование чувствительности опухолевых клеток хронического лимфолейкоза и множественной миеломы к химиопрепаратам in vitro: автореф. дис. …канд. мед. наук: 14.01.12; [Рос. онкол. науч. центр им. Н. Н. Блохина РАМН]. – М., 2012; 26 с. Inshakov A. N. Farmakodinamicheskoe modelirovanie chuvstvitelnosti opuholevyh kletok hronicheskogo limfoleykoza I mnozhestvennoy mielomy k himiopreparatam in vitro. Cand.Diss. [Pharmacodynamic modeling of the sensitivity of tumor cells of chronic lymphocytic leukemia and multiple myeloma for chemotherapeutic agents in vitro. Cand.Diss.] Moscow, 2012. p.26.
4. Конопля Н. Е. Лечение медуллобластомы у детей младше четырех лет // Мед. журн. – 2009. – № 1. – C. 112–114. Konoplya N. E. Treatment of medulloblastoma in children younger four years. Meditsinskyj Zhurnal [Medical journal], 2009, № 1, pp. 112–114.
5. Миронов А. Н., Бунатян Н. Д., Васильева А. Н. и др. Руководство по проведению доклинических исследований лекарственных средств. Часть первая; под ред.: А. Г. Муляра, О. Н. Чиченкова. – М.: Гриф и К, 2012; 944 с. Mironov A. N., Bunatyan N. D., Vasilyeva A. N. et al. “Rukovodstvo po provedeniyu doklinicheskih issledovaniy lekarstvennyh sredstv. Chast’ pervaya; pod red.: A. G. Mulyara, O. N. Chichenkova.” [Guidelines for conducting pre-clinical trials of drugs: Part I.]. Moscow. Grif I K Publ. 2012. 944p.
6. Орлов Ю. А. Комбинированное лечение детей с опухолями головного мозга. Онкология: 2005; 7 (4): 332–38. Orlov Yu.A. Combined treatment of children with brain tumors. Onkologiya [Oncology]. 2005. № 7(4), pp.332–338.
7. Свирновский А. И. Методологические исследования лекарственной чувствительности лейкозных клеток. Пробл. здоровья и экол.: 2011; 3: 89–91. Svirinovskyj A. I. Methodological investigations of drug sensitivity of leukemic cells. Problemy zdorovya I ekologii [Proplems of Health and Ecology], 2011, № 3, pp.89–91.
8. Свирновский А. И., Пасюков В. В. Молекулярные основы феномена химио- и радиорезистентности при опухолевых процессах. Мед. новости: 2007; 11: 7–19. Svirinovskyj A. I., Pasyukov V. V. Molecular basis of the phenomenon of chemo- and radio-resistance in the tumor processes. Meditsinskie Novosti [Medical News}, 2007, № 11, p.7–19.
9. Свирновский А. И., Сергиенко Т. Ф., Алейникова О. В. и др. Скрининг лекарственной чувствительности лейкозных клеток как вариант персонификации терапии опухолевых заболеваний лимфоидной ткани. Здравоохранение. 2012; 7: 8–13. Svirinovskyj A. I., Sergienko T. F., Aleynikova O. V. et al. Screening of drug sensivity of leukemia cells as an alternative of personalization of treatment of neoplastic diseases lymphoid tissue. Zdravoohranenie [Healthcare], 2012, № 7, pp.8–13.
10. Талабаев М. В., Конопля Н. Е. Радикальность нейрохирургического вмешательства в лечении нейроэпителиальных опухолей задней черепной ямки. Мед. панорама: 2009; 3: 10–15. Talabaev M. V., Konoplya N. E. Radicalism of neurosurgical intervention in the treatment of neuroepithelial tumors of the posterior cranial fossa. Meditsinskaya panorama [Medical Panorama], 2009, № 3, pp.10–15.
11. Чехун В. Ф. От системной биологии рака до методологии персонализированного лечения. Онкология: 2012; 14 (2): 84–88. Chekhun V. F. From systemic biology of cancer to methodology of personalized treatment. Onkologiya [Oncology], 2012, № 14(2), pp.84–88.
12. Banerjee D., Longo-Sorbello G., Saydam J. et al. Cytotoxicity and cell growth assays. Cell Biology, Cell Tissue Culture:2006; 0: 315–24.
13. Bertrand J. Begaud-Grimaud G, Bessette B, et al. Cancer stem cells from human glioma cell line are resistant to Fas-induced apoptosis. Intern. J. of Oncology: 2009; 34 (3): 717–27.
14. Bosanquet AG. Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay. Lancet: 1991; 337 (8743): 711–14.
15. Burstein H. J., Mangu P. B., Somerfield M. R. et al. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J. Clin. Oncol.: 2011; 29 (24): 3328–30.
16. Cortazar P., Johnson B. E. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J. Clin. Oncol: 1999; 17(5): 1625–31.
17. Courtenay V. D. A replenishable soft agar colony assay for human tumour sensitivity testing. Recent Results Cancer Res: 1984; 94: 17–34.
18. Fan X., Eberhart C. G. Medulloblastoma stem cells. J. of Clinical Oncology: 2008; 26 (17): 2821–27.
19. Freshney R. I., Masters J. R.W. et al. Animal Cell Culture: a Practical Approach; ed. J.R.W. Masters. 3rd ed. London: Oxford Univ. Press, 2000; 315 p.
20. Freshney R. I., Morgan D. Radioisotopic quantitation in microtitration plates by an autofluorographic method. Cell Biol. Int. Rep: 1978; 2(4): 375–80.
21. Galderisi F, Stark L Li J. et al. Flow cytometric chemosensitivity assay as a predictive tool of early clinical response in acute lymphoblastic leukemia. Pediatr Blood Cancer: 2009; 53 (4): 543–50.
22. Gallion H., Christopherson W. A., Coleman R. L. et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int. J. Gynecol. Cancer: 2006; 16 (1): 194–201.
23. Giasson J., Chen Y. Mysterious stones. Clin. Chem: 2014; 60 (1): 274–75.
24. Gibbons H. M., Dragunow M. Adult human brain cell culture for neuroscience research. Intern. J. Biochem. Cell Biology: 2010; 42: 844–56.
25. Greenberg R. Daniels S., Flanders D. Medical Epidemiology; Lange Medical Books. NY, 2001; 215 p.
26. Herzog T. J., Krivak T. C., Fader A. N. et al. Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am. J. Obstet. Gynecol: 2010; 203 (1): 68. e1–6.
27. Hetland T. E., K rn J., Skrede M. et al. Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index. Cancer Chemother. Pharmacol: 2012; 69 (5): 1307– 14.
28. Jun K. R., Jang S., Chi H. S. et al. Relationship between in vitro chemosensitivity assessed with MTT
29. assay and clinical outcomes in 103 patients with acute leukemia. Korean J. Lab. Med: 2007; 27 (2): 89–95.
30. Kimmel, D. W. Shapiro J. R., Shapiro W. R. In vitro drug sensitivity testing in human gliomas. J. of Neurosurgery: 1987; 66 (2): 161–71.
31. Louis D. N., Ohgaki H., Wiestler O.D et al. WHO Classification of Tumours of the Central Nervous System / ed.: Louis, D. Lyon: IARC Press, 2007: 309 p.
32. Macdonald D. R., Cairncross J. G. Surgery for single brain metastasis. N. Engl. J. Med: 1990; 323 (2): 132–3.
33. Matsuo K., Bond V. K., Eno M. L. et al. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. Int. J. Cancer: 2009; 125 (11): 2721–7.
34. Morgan D., Freshney R. I., Darling J. L. et al. Assay of anticancer drugs in tissue culture: cell cultures of biopsies from human astrocytoma. Br. J. Cancer:1983; 47 (2): 205–14.
35. Pieters R., Huismans D.R, Loonen A. H. et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet: 1991; 338 (8764): 399–403.
36. Ross D. D., Thompson B. W., Ord ez J. V., Joneckis C. C. Improvement of flow-cytometric detection of multidrug-resistant cells by cell-volume normalization of intracellular daunorubicin content. Cytometry: 1989; 10 (2): 185–91.
37. Ross R. A., Spengler B. A. Human neuroblastoma stem cells. Siminars in Cancer Biol: 2007; 17 (3): 241–7.
38. Samson D. J., Seidenfeld J, Ziegler K. et al. Chemotherapy sensitivity and resistance assays: a ystematic review. J. Clin. Oncol: 2004; 22 (17): 3618–30.
39. Sequist L. V., Muzikansky A., Engelman J. A. A new BATTLE in the evolving war on cancer. Cancer Discov: 2011; 1 (1): 14–6.
40. Tomlinson F. H. Lihou M. G., Smith P. J. Comparison of in vitro activity of epipodophyllotoxins with other chemotherapeutic agents in human medulloblastomas. Brit. J. Cancer: 1991; 64 (6): 1051–9.
41. von Hoff D. D., Clark G. M., Stogdill B. J. et al. Prospective clinical trial of a human tumor cloning system. Cancer Res: 1983; 43 (4): 1926–31.
42. Weisenthal L.M, Lippman M. E. Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat. Rep: 1985; 69 (6): 615–32.
43. Wolff J. E., Trilling T, M lenkamp G, et al. Chemosensitivity of glioma cells in vitro: a metaanalysis. J. Cancer Res. Clin. Oncol: 1999; 125 (8/9): 481–6.
44. Xu J. M., Song S. T., Tang Z. M. et al. Neoadjuvant chemotherapy in inoperable, locally advanced, and inflammatory breast carcinoma: a pilot study of MTT assay in vitro and outcome analysis of 10 patients. Am. J. Clin. Oncol: 2001; 24 (3): 259–63.
45. Yataganas X., Strife A., Perez A. et al. Microfluorimetric evaluation of cell kill kinetics with 1-beta-D-arabinofuranosylcytosine. Cancer Res: 1974; 34 (10): 2795–806.
46. Yung W. K. In vitro chemosensitivity testing and its clinical application in human gliomas. Neurosurgical Rev: 1989; 12 (3): 197–203.
47. Yang Z., Wu D., Bui T. et al. A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport. J. Pharmacol. Exp. Ther: 2008; 327 (2): 474–81.
Review
For citations:
CHERNOV A.N., KALJUNOV V.N., KONOPLJA N.E. Developing options for method of assessing the sensitivity of cells intracranial neoplasms to chemotherapeutics in vitro. Malignant tumours. 2015;(3):40-52. (In Russ.) https://doi.org/10.18027/2224-5057-2015-3-40-52
Views:
937
Email this article 